Bayer: Hemophilia Awards Program

The Program supports basic and clinical research and education in hemophilia. Through grants provided to hemophilia care professionals, the program seeks to support the next steps for the next generation of care and treatment options for people with hemophilia worldwide. The Special Project Award is designed to support a wide range of research projects in the field of hemophilia. Funding: $200K over 2 years. Up to 4 new awards will be made annually for each of the two available research awards: Early Career Investigator Award and, Special Project Award. The research priorities for 2012/2013 cycle:
* Prophylaxis regimens for hemophilia patients, including generation of outcomes data and measures of adherence.
* Impact of advancing age on hemophilia patients, including the effect of co-morbidities.
* Projects evaluating how to prevent inhibitor development.
* Clinical studies focusing on treatment modalities for hemophilia.
* Understanding the therapeutic mechanism of action of FVIIa
* Innovations that would lead to improved safety, efficacy or duration of action of rFVIIa.
* Development of experimental in vitro and in vivo models to evaluate therapeutics for the treatment of bleeding disorders
* Discovery or development of new recombinant molecules with potential therapeutic value in bleeding disorders, including those with a longer duration of action
* New delivery options for these molecules, including gene therapy
* Research to define a molecular basis for inhibitor development in hemophilia
* Health outcomes and quality-of-life research related to hemophilia
* Studies designed to increase the diagnosis, recognition and treatment of hemophilia in underserved areas.
http://www.bayer-hemophilia-awards.com/about_the_program